Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016763 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2EGLN1METAP2METAP1 | |
| SCHEMBL27490039 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2EGLN1METAP2METAP1 | |
| SCHEMBL16130357 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2HPGD | |
| SCHEMBL433380 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2HPGD | |
| SCHEMBL28565871 | 0.78 | ALDH1A1 (0.44) | SMN1; SMN2TSHRALDH1A1HPGD | |
| SCHEMBL433417 | 0.77 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6016802 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHREGLN1ALDH1A1GPR35 | |
| SCHEMBL6016803 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHREGLN1ALDH1A1GPR35 | |
| SCHEMBL8250067 | 0.75 | ALDH1A1 (0.39) | SMN1; SMN2TSHRALDH1A1LMNAFAAH | |
| SCHEMBL16130376 | 0.74 | CA1 (0.40) | SMN1; SMN2ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595994-B1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| EP-2595994-B1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-8759523-B2 | Process for preparing pyrano—[2,3-C]pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| US-8759523-B2 | Process for preparing pyrano—[2,3-C]pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| EP-2595994-A2 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | Glaxo Group Limited (GB) | 2013-05-29 | — | — | EP | disclosed |
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | GLAXO GROUP LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | GLAXO GROUP LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2012012391-A2 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012391-A2 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | DHPS, AKR1C3, Q6ZSR9 | SMN1; SMN2 4213/4885TSHR 1193/4885EGLN1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.